Mendus AB: Mendus to host key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Virtual webinar to take place Wednesday, November 30, 2022 @ 1 PM ET / 7PM CET
Upcoming data from Phase 2 ADVANCE II trial of DCP-001 at ASH in December 2022
Mendus AB (“Mendus” publ; IMMU.ST, or “the Company”), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it will host a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients on Wednesday, November 30, 2022, at 1PM to 2:30PM Eastern Time / 7PM to 8:30PM Central European Time. To register for the event, please click here.
The event will feature two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital for a discussion on the current treatment landscape in AML, and the emergence of maintenance therapy as a new paradigm for treatment of AML patients in remission. A live question & answer session will follow the main session.
The discussion will also set the stage for the upcoming data that will be presented in an oral presentation at the American Society of Hematology Annual Meeting on December 12, 2022 from the ongoing Phase 2 ADVANCE II study evaluating DCP-001 as a potential maintenance therapy for AML patients in remission with measurable residual disease (MRD). The results will include the most recent survival data from the study, as well as extensive immunomonitoring data.
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education at the Hematology division at Yale Cancer Center. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University, where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award.
Uwe Platzbecker is the Director of the Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology at the Leipzig University Hospital, Leipzig, Germany. Prof. Platzbecker completed his medical studies at the Technical University of Dresden, Dresden, Germany, qualifying in 1996. He obtained his doctorate in medicine in 1997, completed his post doctorate degree in 2001 at the Fred Hutchinson Cancer Research Center, Seattle, WA, and received his professorship for translational hematology at the Technical University of Dresden in 2012. Prof. Dr. Platzbecker has received many awards, including the Chugai Science Award and the Van-Bekkum-Award of the European Society for Blood and Marrow Transplantation (EBMT) on behalf of the German MDS Study Group.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Benteler terminates the previously-announced sale to Tenaris of its Shreveport, Louisiana pipe manufacturing plant5.2.2023 19:20:07 CET | Press release
LUXEMBOURG, Feb. 05, 2023 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced today that Benteler North America Corporation has exercised its right to unilaterally terminate, effective immediately, the previously-announced agreement for the sale to Tenaris of 100% of the shares of U.S. steel pipe producer Benteler Steel & Tube Manufacturing Corporation. Tenaris is a leading global supplier of steel tubes and related services for the world’s energy industry and certain other industrial applications. Giovanni Sardagna Tenaris 1-888-300-5432 www.tenaris.com
SKEL fjárfestingafélag hf.: Amendment to the financial calendar and previously disclosed information4.2.2023 19:13:54 CET | Press release
The audit of SKEL’s financial statements for the year 2022, which has not been finalized, has resulted in a change of its presentation due to the company‘s transition into an investment company. Shares in subsidiaries were capitalized according to the equity method until year end 2021 but are recognised at fair value through profit or loss from the beginning of 2022. This results in a previously unrealized fair value change from 2021 of ISK 2.6 billion that was formerly accounted for directly through equity, will instead be recognised in the income statement for 2022. This change of presentation has no effect of previously announced equity for year-end 2022 of ISK 33.0-33.5 billion. Further, this does not alter the company’s ability to pay dividend. The company‘s estimated earnings net of tax will, however, increase by ISK 2.6 billion and amount to ISK 17.1-17.6 billion instead of ISK 14.5-15.0 billion as was previously announced on 31 January 2023. The company has decided to change th
City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing4.2.2023 05:18:05 CET | Press release
Vacaville high school students explore local career opportunities to honor National Career Technical Education Month VACAVILLE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- February is National Career Technical Education (CTE) Month, and the City of Vacaville joined the celebration by hosting a field trip for 58 Vacaville high school students February 3. The field trip included several locations around Vacaville and Solano County to explore advanced manufacturing and biotechnology. Every February, the Association for Career and Technical Education encourages communities to celebrate CTE Month, to raise awareness of the role that CTE has in readying learners for college and career success. This is also a time when the City of Vacaville recognizes and celebrates the contributions and achievements of community CTE partners including Solano Community College (SCC) and The Workforce Development Board of Solano County. “This field trip is an excellent opportunity for Vacaville’s young people to
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®4.2.2023 00:30:00 CET | Press release
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like abscesses that can lead to open wounds and irreversible scarring in the most intimate parts of the body2,3 There is only one approved therapy for HS and many patients, even those on treatment, still experience uncontrolled symptoms4 Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials
Maha Energy meddelar reserv- och resursrapport per 31 december 20223.2.2023 21:45:00 CET | Pressemelding
McDaniel & Associates Consultants Ltd. (“McDaniel”) har genomfört sin första utvärdering av Maha Energy AB:s (publ) (”Maha” eller ”Bolaget”) reserver och resurser. Väsentliga förändringar från föregående års reserv- och resurssiffror är hänförliga till: att den tidigare annonserade utfarmningen och Joint Operating Agreement avtalet med Mafraq Energy LLC avseende Block 70 i Oman slutförs. Maha är operatör på Block 70 och Mahas licensandel minskar till 65 procent till följd härav.att den tidigare offentliggjorda transaktionen avseende den förväntade avyttringen av Mahas brasilianska verksamhet och följaktligen bolagets olje- och gastillgångar, där försäljningsavtalet undertecknades den 27 december 2022, resulterar i att inga reserver redovisas för fälten Tie och Tartaruga. Mahas reserver1 per 31 december 2022 2022 Maha Energy AB bruttoreserver före skatt (miljoner fat)KategoriTillgångar i USAMafraqTotalt1P1,340,421,762P2,740,523,263P3,590,624,21 De huvudsakliga förändringarna i årets res